BRAF and melanoma: We also tested two lines with distinct drug sensitivities based on alternative genomic contexts (one BRAF mutant melanoma (A375) sensitive to RAF inhibition and one KRAS wild type colorectal cancer (LIM1215) sensitive to EGFR inhibition).